Thomas Lenz
Corneal and Contact Management · Willmar, MNNPI 1093997843
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 18 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by Alcon at 26.8% of the total. Reporting peaked in 2019 at $215 and has fallen 61.7% since, to $82 in 2025. That places this record below the midpoint for corneal and contact management clinicians in MN, where the typical reported total is $507.
Across 18 payments — averaging $25.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$123
- Johnson & Johnson Surgical Vision, Inc.$120
- The Cameron-ehlen Group, Inc.$70
- Biotissue Holdings Inc.$43
- Oyster Point Pharma, Inc.$28
- Sight Sciences, Inc.$25
- plus $50 from 3 others
What the payments were for
- Food & beverage$458100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 6 | $123 |
| Johnson & Johnson Surgical Vision, Inc. | 3 | $120 |
| The Cameron-ehlen Group, Inc. | 1 | $70 |
| Biotissue Holdings Inc. | 2 | $43 |
| Oyster Point Pharma, Inc. | 2 | $28 |
| Sight Sciences, Inc. | 1 | $25 |
| Tarsus Pharmaceuticals, Inc. | 1 | $19 |
| Rxsight Inc | 1 | $18 |
| AbbVie | 1 | $13 |
How this compares
$458 in reported general payments places this provider in the 45th percentile of 30 corneal and contact management providers in Minnesota.
See all corneal and contact management providers in Minnesota →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 41 | $44,395 |
| Restasis MultidoseCyclosporine | 14 | $8,285 |
| Latanoprost | 515 | $7,622 |
| RhopressaNetarsudil Mesylate | 20 | $6,213 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 27 | $5,434 |
| Prednisolone Acetate | 111 | $4,161 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 141 | $2,676 |
| Brimonidine Tartrate | 39 | $1,965 |
| TafluprostTafluprost/Pf | 11 | $1,772 |
| Timolol Maleate | 165 | $1,714 |
| Fluorometholone | 15 | $1,191 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 34 | $473 |
| ValacyclovirValacyclovir Hcl | 19 | $311 |
| Dorzolamide Hcl | 15 | $249 |
| Ofloxacin | 13 | $159 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Restasis Multidose | $13 | $52,68055 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 30 corneal and contact management providers in Minnesota.
Other corneal and contact management in Willmar
- Michael NovakWillmar$2K
- Michael NagelWillmar$767
- Ahmad FahmyMinneapolis$222K
- Scott HauswirthBloomington$73K
- Mark BuboltzBloomington$6K
- Tina McCartyFridley$3K
- Thomas EltonEdina$2K
- Alicia AlvaradoFridley$2K
- Johnna HobbsBloomington$2K
- Robert DingaOakdale$962
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.